2010 Annual Scientific Meeting and Exposition 2010 Annual ...

Novartis cordially invitesfollowing programs atTEKTURNA ExploringDirect Renin InhibitionHoward Weintraub, MD, FACCClinical Associate ProfessorDept. of Medicine/CardiologyNew York School of MedicineClinical DirectorNew York University Center for thePrevention of Cardiovascular DiseaseNew York, NYLawrence Byrd, MDClinical Assistant Professor of MedicineUniversity of Medicine and DentistryNewark, NJChief, Hypertension SectionSt. Barnabas Medical CenterLivingston, NJMay 1, 2010 • 5:30–6:30 PMSpace is limited. Register at Booth 1100 in the Hypertension Resource Pavilion (Americas Hall 1,3rd Floor) or register on-site at the Innovations Theater (Americas Hall 1, 3rd Floor).IndicationTEKTURNA and VALTURNA are indicated for the treatment of hypertensionin adults.TEKTURNA may be used alone or in combination with other antihypertensiveagents. VALTURNA may be substituted for the titrated components.VALTURNA may be used in patients whose blood pressure is notadequately controlled on aliskiren or any ARB monotherapy. VALTURNAis also indicated as initial therapy in patients who are likely to needmultiple drugs to achieve their blood pressure goals. It is not knownwhether additive effects are present when TEKTURNA is used withACE inhibitors or beta-blockers. Use with maximal doses of ACE inhibitorshas not been adequately studied.The choice of VALTURNA as initial therapy should be based on anassessment of potential benefits and risks. The decision to use acombination as initial therapy should be individualized and shouldbe shaped by considerations such as baseline blood pressure, target BPgoal, and the incremental likelihood of achieving goal with a combinationproduct compared to monotherapy.Sponsored by:© 2010 Novartis 3/10 CVF-900422